<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0602256835
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HEMLIBRA 150 MG/ML SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EMICIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52475.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CHUGAI PHARMACEUTICAL CO LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CHUGAI PHARMACEUTICAL CO LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ROCHE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BX06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia&nbsp;A with or without factor VIII inhibitors.Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.</strong></p><p dir="ltr"><strong>HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ol><li dir="ltr">&nbsp;</li></ol><ol><li dir="ltr"><p dir="ltr"><strong>Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:</strong></p></li></ol><ul><li dir="ltr"><p dir="ltr"><strong>Are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.</strong></p></li></ul><p dir="ltr"><strong>Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</strong></p><ol><li dir="ltr"><p dir="ltr"><strong>Using other medicines, herbal or dietary supplements:</strong></p></li></ol><p dir="ltr"><strong>Hypercoagulability with Concomitant Use of aPCC:</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Clinical experience suggests that a drug interaction exists with HEMLIBRA and aPCC&nbsp;</strong></p></li></ul><p><br />&nbsp;</p><ol><li dir="ltr"><p dir="ltr"><strong>Driving and using machines:</strong></p></li></ol><p dir="ltr"><strong>This medicine is not likely to affect your ability to drive or use machines.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ol><li dir="ltr">&nbsp;<ul><li dir="ltr"><p dir="ltr"><strong>Use HEMLIBRA exactly as prescribed by your healthcare provider.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>You may continue prophylactic use of FVIII for the first week of HEMLIBRA prophylaxis.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>HEMLIBRA is given as an injection under your skin (subcutaneous injection) by you or a caregiver.&nbsp;</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Your healthcare provider should show you or your caregiver how to prepare, measure, and inject your dose of HEMLIBRA before you inject yourself for the first time.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Do not attempt to inject yourself or another person unless you have been taught how to do so by a healthcare provider.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Your healthcare provider will prescribe your dose based on your weight. If your weight changes, tell your healthcare provider.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>You will receive HEMLIBRA 1 time a week for the first four weeks. Then you will receive a maintenance dose as prescribed by your healthcare provider.&nbsp;</strong></p></li><li dir="ltr"><p dir="ltr"><strong>If you miss a dose of HEMLIBRA on your scheduled day, you should give the dose as soon as you remember. You must give the missed doseas soon as possible before the next scheduled&nbsp; dose, and then continue with your normal dosing schedule. Do not give two doses on the same day to make up for a missed dose.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.</strong></p></li></ul></li></ol>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>See &ldquo;What is the most important information I should know about HEMLIBRA?&rdquo;</strong></p><p dir="ltr"><strong>The most common side effects of HEMLIBRA include:&nbsp;</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>redness, tenderness, warmth, or itching at the site of injection</strong></p></li><li dir="ltr"><p dir="ltr"><strong>headache</strong></p></li><li dir="ltr"><p dir="ltr"><strong>joint pain</strong></p></li></ul><p dir="ltr"><strong>These are not all of the possible side effects of HEMLIBRA.&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ol><li dir="ltr">&nbsp;<ul><li dir="ltr"><p dir="ltr"><strong>Store HEMLIBRA in the refrigerator at 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C). Do not freeze.&nbsp;</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Store HEMLIBRA in the original carton to protect the vials from light.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Do not shake HEMLIBRA.</strong></p></li></ul></li></ol><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>If needed, unopened vials of HEMLIBRA can be stored out of the refrigerator and then returned to the refrigerator. HEMLIBRA should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86&deg;F (30&deg;C).</strong></p></li></ul><ul><li dir="ltr"><p dir="ltr"><strong>After HEMLIBRA is transferred from the vial to the syringe, HEMLIBRA should be used right away.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Throw away (dispose of) any unused HEMLIBRA left in the vial.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Keep HEMLIBRA and all medicines out of the reach of children.</strong></p></li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ol><li dir="ltr">&nbsp;</li></ol><ol><li dir="ltr"><p dir="ltr"><strong>Contents of the pack and other information:What are the ingredients in HEMLIBRA?</strong></p></li></ol><p dir="ltr"><strong>Active ingredient: emicizumab-kxwh.</strong></p><p dir="ltr"><strong>Inactive ingredients: L arginine, L histidine, poloxamer 188, and L aspartic acid.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
HEMLIBRA is available as a colorless to slightly yellow solution in single-dose vials.Injection:
30 mg/mL 
60 mg/0.4 mL 
105 mg/0.7 mL 
150 mg/mL 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124,&nbsp;</strong></p><p dir="ltr"><strong>CH-4070 Basel,&nbsp;</strong></p><p dir="ltr"><strong>Switzerland.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised October 2018.

To report any side effect(s):
Saudi Arabia:
The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
SFDA call center: 19999 
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc

Other GCC States:
Please contact the relevant competent authority.

Council of Arab Health Ministers:
This is a Medicament
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you. 
Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament. 
The doctor and the pharmacist are the experts in medicines, their benefits and risks. 
Do not by yourself interrupt the period of treatment prescribed for you. 
Do not repeat the same prescription without consulting your doctor. 
Keep all medicaments out of reach of children. 
Council of Arab Health Ministers
Union of Arab Pharmacists


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl"><strong>هيمليبرا دواء وصفي، يستخدم للوقاية الروتينية لمنع أو تقليل تكرار حدوث نوبات النزيف للكبار والأطفال (حديثي الولادة والأكبر سناً)، الذين يعانون من الهيموفيليا أ مع أو بدون مثبطات عامل التجلط الثامن.</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الهيموفيليا أ هي حالة من النزيف قد يولد بها الأشخاص والتي يكون فيها عامل تخثر الدم غائبا أو به قصور (العامل 8) الأمر الذي يمنع الدم من التجلط بشكل طبيعي.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>هيمليبرا هو عبارة عن جسم مضاد علاجي يعوض عوامل التخثر الطبيعية الناقصة لمساعدة الدم على التجلط.</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>أولاً:&nbsp; أخبر طبيبك قبل استخدام هيمليبرا عن حالتك الصحية بدقة ويشمل ذلك:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الحمل أو التخطيط للحمل.&nbsp; فمن غير المعروف احتمالية تأثير دواء هيمليبرا على الجنين.&nbsp; ويجب على النساء المعرضات للحمل استخدام موانع الحمل أثناء العلاج بهذا الدواء.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإرضاع أو التخطيط للإرضاع.&nbsp; فمن غير المعروف احتمالية مرور دواء هيمليبرا إلى الطفل الرضيع عبر حليب الثدي.</strong></p></li></ul><p dir="rtl"><strong>أخبر طبيبك عن كافة الأدوية التي تتناولها، ويشمل ذلك الأدوية التي تصرف بروشتة طبية أو بدون روشتة طبية وأيضا الفيتامينات أو المكملات الغذائية والأعشاب.&nbsp; احتفظ بقائمة بهذه الأدوية لعرضها على الطبيب والصيدلي عند استخدام دواء جديد.</strong></p><p dir="rtl"><strong>ثانياً:&nbsp; استخدام الأدوية الأخرى والمكملات الغذائية والأعشاب:</strong></p><p dir="rtl"><strong>فرط تخثر الدم مع الاستخدام المتزامن لمركزات البروثرومبين.</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يتضح من خلال التجارب السريرية حدوث تفاعل بين عقار هيمليبرا ومركزات البروثرومبين الأخرى.</strong></p></li></ul><p dir="rtl"><strong>ثالثاً:&nbsp; قيادة السيارات واستخدام الآلات:</strong></p><p dir="rtl"><strong>من غير المحتمل أن يؤثر هذا الدواء على قدرتك على قيادة أو استخدام الآلات.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ol><li dir="rtl"><p dir="rtl"><strong>طريقة استخدام هيمليبرا:</strong></p></li></ol><ul><li dir="rtl"><p dir="rtl"><strong>اتبع تعليمات الطبيب بعناية عند استخدام هيمليبرا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ابتعد عن الاستخدام الوقائي للعوامل المساعدة على التخثر قبل يوم واحد من البدء في استخدام هيمليبرا (الاستخدام الوقائي).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>من المحتمل أن تستمر باستخدام عامل التجلط الثامن وقائياً لمدة اسبوع بالتزامن مع استخدام هيمليبرا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يتم إعطاؤك هيمليبرا على هيئة حقن تحت الجلد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب عليك اتباع تعليمات الطبيب المتعلقة بكيفية تجهيز وقياس وحقن جرعتك من هيمليبرا قبل حقن نفسك للمرة الأولى.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>لا تحاول حقن نفسك أو حقن شخص آخر ما لم تكن مدربا على إعطاء الحقن.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>طبيبك هو الذي يصف لك الجرعة بناء على الوزن.&nbsp; ويجب عليك استشارة الطبيب في حالة حدوث تغير في وزنك.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>سيتم اعطاؤك هيمليبرا مرة واحدة اسبوعياً ولمدة أربع اسابيع. بعد ذلك ستستخدم جرعة وقائية حسبما يصفها لك الطبيب.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة نسيان موعد جرعة هيمليبرا في موعدها المجدول، يجب عليك الحصول على الجرعة حال تذكرها. يجب عليك أخذ الجرعة الفائتة في أسرع وقت ممكن وذلك قبل موعد الجرعة التالية ثم الاستمرار على جدول الجرعات المعتاد.&nbsp; لا يجب أخذ جرعتين في نفس اليوم لتعويض الجرعة الفائتة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قد يؤثر هيمليبرا على نتائج التحاليل التي تقيس تخثر الدم وقد يؤدي إلى قراءة خاطئة.&nbsp; تحدث إلى الطبيب عن مدى تأثير ذلك.</strong></p></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>انظر &quot;المعلومات الهامة التي يجب عليك معرفتها عن هيمليبرا&quot;.</strong></p><p dir="rtl"><strong>وتشمل أكثر الآثار الجانبية شيوعا لدواء هيمليبرا ما يلي:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الاحمرار أو الألم أو السخونة أو الحكة مكان الحقن.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الصداع</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم المفاصل</strong></p></li></ul><p dir="rtl"><strong>وهذه ليست جميع الآثار الجانبية المرتبطة بعقار هيمليبرا.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يخزن هيمليبرا من قبل أفراد الرعاية الصحية بالمستشفى أو العيادة.&nbsp; وفيما يلي التفاصيل الهامة الخاصة بالتخزين:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يخزن هيمليبرا في الثلاجة في درجة حرارة 36 &ndash; 46 درجة فهرنهايت (2 &ndash; 8 درجة مئوية) دون تجميد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يخزن هيمليبرا في العبوة الكرتونية الأصلية لحماية الأمبولات من الضوء.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>لا ترج العبوة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يمكن تخزين الأمبولات غير المفتوحة من هيمليبرا خارج الثلاجة عند الحاجة ثم إعادتها إلى الثلاجة.&nbsp; يجب عدم تخزين هيمليبرا خارج الثلاجة لمدة يزيد مجموعها عن 7 أيام أو&nbsp; في درجة حرارة أعلى من 86 درجة فهرنهايت (30 درجة مئوية).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب استخدام الحقنة مباشرة بعد نقل هيمليبرا من الأمبول إلى إبرة الحقن (السرنجة).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يحفظ هيمليبرا وجميع الأدوية بعيدا عن متناول الأطفال.</strong></p></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>ما هي مكونات هيمليبرا؟</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>المادة الفعالة:&nbsp; إميسيزوماب-كي اكس دبليو اتش.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>المواد غير الفعالة:&nbsp; إل أرجينين، إل هيستيدين، بولوكسامر 188، إل حمض الأسبرتيك.</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شكل عقار هيمليبرا ومحتويات العبوة:</strong></p><p dir="rtl"><strong>هيمليبرا عبارة عن سائل شفاف عديم اللون إلى مصفر قليلا في أمبولات للحقن مرة واحدة:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>30 مج / مل</strong></p></li><li dir="rtl"><p dir="rtl"><strong>60 مج / 0.4 مل</strong></p></li><li dir="rtl"><p dir="rtl"><strong>105 مج / 0.7 مل</strong></p></li><li dir="rtl"><p dir="rtl"><strong>150 مج / مل</strong></p></li></ul><p><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شركة ف. هوفمان لا روش المحدودة</strong></p><p dir="rtl"><strong>142 جرينزاهاشتراس</strong></p><p dir="rtl"><strong>CH-4070 بازل</strong></p><p dir="rtl"><strong>سويسرا</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذ النشرة أكتوبر 2018.

للإبلاغ عن الآثار الجانبية

المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
فاكس: 7662-205-11-966+
او اتصل بالمركز على رقم 2038222-11-966+ تحويلة: 2340-2356-2317
مركز الاتصال الموحد 19999 
بريد الكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: www.sfda.gov.sa

دول مجلس التعاون الخليجي الأخرى:
يرجى التواصل مع الهيئة المعنية ذات الصلة.

مجلس وزارات الصحة العربية
هذا المنتج دوائي
قد تؤثر المنتجات الدوائية على صحتك، ويعد استهلاكه بخلاف الطريقة المحددة أمرًا خطيرًا.
اتبع وصفة الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء بدقة.
الطبيب والصيدلي خبراء في المنتجات الدوائية وفوائدها ومخاطرها.
لا تقطع فترة العلاج المحددة لك من تلقاء نفسك.
لا تكرر استخدام نفس الوصفة الطبية دون استشارة طبيبك.
احتفظ بجميع المنتجات الدوائية بعيدًا عن متناول الأطفال.






مجلس وزارات الصحة العربية
اتحاد الصيادلة العرب


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use
Black Box warning 
WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM 

Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emicizumab-kxwh is a humanized monoclonal modified immunoglobulin G4 (IgG4) bispecific antibody binding factor IXa and factor X. Emicizumab-kxwh has an approximate molecular weight of 145.6 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells. Emicizumab-kxwh has no structural relationship or sequence homology to FVIII and, as such, does not induce or enhance the development of direct inhibitors to FVIII.
HEMLIBRA (emicizumab-kxwh) injection is a sterile, preservative-free, colorless to slightly yellow solution for subcutaneous injection supplied in single-dose vials containing emicizumab-kxwh at 30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL, or 150 mg/mL. 
Each single-dose 30 mg vial contains a 1 mL solution of emicizumab-kxwh (30 mg), L-arginine (26.1 mg), L-histidine (3.1 mg), and poloxamer 188 (0.5 mg), adjusted to pH 6.0 with L-aspartic acid.
Each single-dose 60 mg vial contains a 0.4 mL solution of emicizumab-kxwh (60 mg), L-arginine (10.5 mg), L-histidine (1.2 mg), and poloxamer 188 (0.2 mg), adjusted to pH 6.0 with L-aspartic acid.
Each single-dose 105 mg vial contains a 0.7 mL solution of emicizumab-kxwh (105 mg), L-arginine (18.3 mg), L-histidine (2.2 mg), and poloxamer 188 (0.4 mg), adjusted to pH 6.0 with L-aspartic acid.
Each single-dose 150 mg vial contains a 1 mL solution of emicizumab-kxwh (150 mg), L-arginine (26.1 mg), L-histidine (3.1 mg), and poloxamer 188 (0.5 mg), adjusted to pH 6.0 with L-aspartic acid.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
HEMLIBRA is available as a colorless to slightly yellow solution in single-dose vials.
Injection:
30 mg/mL 
60 mg/0.4 mL 
105 mg/0.7 mL 
150 mg/mL 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia&nbsp;A (congenital factor VIII deficiency) with or without factor&nbsp;VIII inhibitors.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li dir="ltr"><p><strong>Recommended Dosage</strong></p></li></ul><p dir="ltr"><strong>For subcutaneous use only.</strong></p><p dir="ltr"><strong>The recommended loading dose is 3&nbsp;mg/kg by subcutaneous injection once weekly for the first 4&nbsp;weeks, followed by a maintenance dose of:</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>1.5 mg/kg once every week, or</strong></p></li><li dir="ltr"><p dir="ltr"><strong>3 mg/kg once every two weeks, or</strong></p></li><li dir="ltr"><p dir="ltr"><strong>6 mg/kg once every four weeks.</strong></p></li></ul><p dir="ltr"><strong>The selection of a maintenance dose should be based on healthcare provider preference with consideration of regimens that may increase patient adherence.</strong></p><p dir="ltr"><strong>Discontinue the prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.</strong></p><p dir="ltr"><strong>The prophylactic use of factor VIII (FVIII) products may be continued during the first week of HEMLIBRA prophylaxis.&nbsp;</strong></p><p dir="ltr"><strong>Missed Dose</strong></p><p dir="ltr"><strong>If a dose of HEMLIBRA is missed administer as soon as possible and then resume usual dosing schedule. Do not administer two doses on the same day to make up for a missed dose.</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p dir="ltr"><strong>Pediatric Use</strong></p><p dir="ltr"><strong>The safety and efficacy of HEMLIBRA have been established in pediatric patients. Use of HEMLIBRA in pediatric patients with hemophilia A is supported by two randomized trials (HAVEN 1 and HAVEN 3) and two single-arm trials (HAVEN 2 and HAVEN 4). All clinical trials included pediatric patients in the following age group: 47 adolescents (12 years up to less than 18 years). Only HAVEN 2 included pediatric patients in the following age groups: 55 children (2 years up to less than 12 years) and five&nbsp;infants (1&nbsp;month up to less than 2 years). No differences in efficacy were observed between the different age groups [see 5.1 Pharmacodynamic properties, Clinical efficacy and safety].</strong></p><p dir="ltr"><strong>The steady-state plasma trough concentrations of emicizumab-kxwh were comparable in adult and pediatric patients older than 6 months at equivalent weight-based doses. Lower concentrations of emicizumab-kxwh were predicted in pediatric patients less than 6 months old [see 5.2 Pharmacokinetics properties].&nbsp;</strong></p><p dir="ltr"><strong>In general, the adverse reactions in HEMLIBRA-treated pediatric patients were similar in type to those seen in adult patients with hemophilia A [see 4.8 Undesirable effects].</strong></p><p dir="ltr"><strong>Geriatric Use</strong></p><p dir="ltr"><strong>Clinical studies of HEMLIBRA did not include a sufficient number of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</strong></p><p>&nbsp;</p><ul><li dir="ltr"><p><strong>Preparation and Administration</strong></p></li></ul><p dir="ltr"><strong>HEMLIBRA is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject, or the patient&rsquo;s caregiver may administer HEMLIBRA, if a healthcare provider determines that it is appropriate. Self-administration is not recommended for children less than&nbsp;7 years of age.</strong></p><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>Visually inspect HEMLIBRA for particulate matter and discoloration before administration. HEMLIBRA for subcutaneous administration is a colorless to slightly yellow solution. Do not use if particulate matter is visible or product is discolored.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>A syringe, a transfer needle and an injection needle are needed to withdraw HEMLIBRA solution from the vial and inject it subcutaneously.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Refer to the HEMLIBRA &ldquo;Instructions for Use&rdquo; for handling instructions when combining vials. Do not combine HEMLIBRA vials of different concentrations in a single injection.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Administer doses of HEMLIBRA up to 1 mL with a 1 mL syringe. A 1 mL syringe fulfilling the following criteria may be used: Transparent polypropylene or polycarbonate syringe with Luer-Lock tip, graduation 0.01&nbsp;mL, sterile, for injection only, single-use, latex-free and non-pyrogenic, commercially available in the US.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Administer doses of HEMLIBRA greater than 1 mL and up to 2 mL with a 2 mL or 3 mL syringe. A 2 mL or 3 mL syringe fulfilling the following criteria may be used: Transparent polypropylene or polycarbonate syringe with Luer-Lock tip, graduation 0.1&nbsp;mL, sterile, for injection only, single-use, latex-free, and non-pyrogenic, commercially available in the US.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>A transfer needle fulfilling the following criteria may be used: Stainless steel needle with Luer-Lock connection, sterile, 18&nbsp;gauge, length 1 to 1&frac12; inch, single bevel or semi-blunted tip, single-use, latex-free, and non-pyrogenic, commercially available in the US.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>An injection needle fulfilling the following criteria may be used: Stainless steel with Luer-Lock connection, sterile, 26 gauge (acceptable range: 25 &ndash; 27 gauge), length preferably 3/8 inch or maximal length &frac12;&nbsp;inch, single-use, latex-free and non-pyrogenic, including needle safety feature, commercially available in the US.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Administer each injection at a different anatomic location (upper outer arms, thighs, or any quadrant of abdomen) than the previous injection. An injection should never be given into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact. Administration of HEMLIBRA in the upper outer arm should only be performed by a caregiver or healthcare provider.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Discard any unused HEMLIBRA remaining in the single-dose vial.</strong></p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li dir="ltr"><p><strong>Thrombotic Microangiopathy Associated with HEMLIBRA and aPCC</strong></p></li></ul><p dir="ltr"><strong>Cases of thrombotic microangiopathy (TMA) were reported from clinical trials when on average a cumulative amount of &gt;100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. In clinical trials, thrombotic microangiopathy was reported in 0.8% of patients (3/391) and in 8.1% of patients (3/37) who received at least one dose of aPCC. Patients presented with thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury, without severe deficiencies in ADAMTS13 activity.&nbsp;</strong></p><p dir="ltr"><strong>Evidence of improvement was seen within one week following discontinuation of aPCC. One patient resumed HEMLIBRA following resolution of TMA.&nbsp;</strong></p><p dir="ltr"><strong>Consider the benefits and risks if aPCC must be used in a patient receiving HEMLIBRA prophylaxis. Monitor for the development of TMA when administering aPCC. Immediately discontinue aPCC and interrupt HEMLIBRA prophylaxis if clinical symptoms and/or laboratory findings consistent with TMA occur, and manage as clinically indicated. Consider the benefits and risks of resuming HEMLIBRA prophylaxis following complete resolution of TMA on a case-by-case basis.</strong></p><p>&nbsp;</p><ul><li dir="ltr"><p><strong>Thromboembolism Associated with HEMLIBRA and aPCC</strong></p></li></ul><p dir="ltr"><strong>Thrombotic events were reported from clinical trials when on average a cumulative amount of &gt;100 U/kg/24 hours of aPCC was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. In clinical trials, thrombotic events were reported in 0.5% of patients (2/391) and in 5.4% of patients (2/37) who received at least one dose of aPCC.&nbsp;</strong></p><p dir="ltr"><strong>No thrombotic event required anticoagulation therapy. Evidence of improvement or resolution was seen within one month following discontinuation of aPCC. One patient resumed HEMLIBRA following resolution of thrombotic event.</strong></p><p dir="ltr"><strong>Consider the benefits and risks if aPCC must be used in a patient receiving HEMLIBRA prophylaxis. Monitor for the development of thromboembolism when administering aPCC. Immediately discontinue aPCC and interrupt HEMLIBRA prophylaxis if clinical symptoms, imaging, or laboratory findings consistent with thromboembolism occur, and manage as clinically indicated. Consider the benefits and risks of resuming HEMLIBRA prophylaxis following complete resolution of thrombotic events on a case-by-case basis.&nbsp;</strong></p><ul><li dir="ltr"><p><strong>Laboratory Coagulation Test Interference</strong></p></li></ul><p dir="ltr"><strong>HEMLIBRA affects intrinsic pathway clotting-based laboratory tests, including activated clotting time (ACT), activated partial thromboplastin time (aPTT), and all assays based on aPTT, such as one-stage factor VIII (FVIII) activity (Table 1). Therefore, intrinsic pathway clotting-based laboratory test results in patients treated with HEMLIBRA should not be used to monitor HEMLIBRA activity, determine dosing for factor replacement or anti-coagulation, or measure FVIII inhibitor titers. Laboratory tests affected and unaffected by HEMLIBRA are shown in Table 1.</strong></p><p dir="ltr"><strong>Table&nbsp;1 Coagulation Test Results Affected and Unaffected by HEMLIBRA</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Results Affected by HEMLIBRA</strong></p></td><td><p dir="ltr"><strong>Results Unaffected by HEMLIBRA</strong></p></td></tr><tr><td><p dir="ltr"><strong>Activated partial thromboplastin time (aPTT)</strong></p><p dir="ltr"><strong>Bethesda assays (clotting-based) for FVIII inhibitor titers</strong></p><p dir="ltr"><strong>One-stage, aPTT-based, single-factor assays</strong></p><p dir="ltr"><strong>aPTT-based Activated Protein C Resistance (APC-R)</strong></p><p dir="ltr"><strong>Activated clotting time (ACT)</strong></p></td><td><p dir="ltr"><strong>Bethesda assays (bovine chromogenic) for FVIII inhibitor titers</strong></p><p dir="ltr"><strong>Thrombin time (TT)</strong></p><p dir="ltr"><strong>One-stage, prothrombin time (PT)-based, single-factor assays</strong></p><p dir="ltr"><strong>Chromogenic-based single-factor assays other than FVIII*</strong></p><p dir="ltr"><strong>Immuno-based assays (i.e., ELISA, turbidimetric methods)</strong></p><p dir="ltr"><strong>Genetic tests of coagulation factors (e.g., Factor V Leiden, Prothrombin 20210)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>*For important considerations regarding FVIII chromogenic activity assays, see section 4.5 Interaction with other medicinal products and other forms of interaction</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li dir="ltr"><p dir="ltr"><strong>Hypercoagulability with Concomitant Use of aPCC,&nbsp;</strong></p></li></ul><p dir="ltr"><strong>Clinical experience suggests that a drug interaction exists with HEMLIBRA and aPCC [see section 4.4 Special warnings and precautions for use and 4.8 Undesirable effects].</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Drug-Laboratory Test Interactions</strong></p></li></ul><p dir="ltr"><strong>HEMLIBRA restores the tenase cofactor activity of missing activated factor VIII (FVIIIa). Coagulation laboratory tests based on intrinsic clotting (i.e., aPTT) measure the total clotting time including time needed for activation of FVIII to FVIIIa by thrombin. Such intrinsic pathway-based tests will yield overly shortened clotting times with HEMLIBRA, which does not require activation by thrombin. The overly shortened intrinsic clotting time will then disturb all single-factor assays based on aPTT, such as the one-stage FVIII activity assay; however, single-factor assays utilizing chromogenic or immuno-based methods are unaffected by HEMLIBRA and may be used to monitor coagulation parameters during treatment, with specific considerations for FVIII chromogenic activity assays as described below.</strong></p><p dir="ltr"><strong>Chromogenic FVIII activity tests may be manufactured with either human or bovine coagulation proteins. Assays containing human coagulation factors are responsive to HEMLIBRA but may overestimate the clinical hemostatic potential of HEMLIBRA. In contrast, assays containing bovine coagulation factors are insensitive to HEMLIBRA (no activity measured) and can be used to monitor endogenous or infused FVIII activity, or to measure anti-FVIII inhibitors.</strong></p><p dir="ltr"><strong>HEMLIBRA remains active in the presence of inhibitors against FVIII, so it will produce a false-negative result in clotting-based Bethesda assays for functional inhibition of FVIII. Instead, a chromogenic Bethesda assay utilizing a bovine-based FVIII chromogenic test that is insensitive to HEMLIBRA may be used.</strong></p><p dir="ltr"><strong>Due to the long half-life of HEMLIBRA, effects on coagulation assays may persist for up to 6 months after the last dose [see section 5.2 Pharmacokinetics properties].</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li dir="ltr"><p dir="ltr"><strong>Pregnancy</strong></p></li></ul><p dir="ltr"><strong>Risk Summary</strong></p><p dir="ltr"><strong>There are no available data on HEMLIBRA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Animal reproduction studies have not been conducted with emicizumab-kxwh. It is not known whether HEMLIBRA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. HEMLIBRA should be used during pregnancy only if the potential benefit for the mother outweighs the risk to the fetus.</strong></p><p dir="ltr"><strong>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2&nbsp;&minus;&nbsp;4% and 15&nbsp;&minus;&nbsp;20%, respectively.</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Lactation</strong></p></li></ul><p dir="ltr"><strong>Risk Summary</strong></p><p dir="ltr"><strong>There is no information regarding the presence of emicizumab-kxwh in human milk, the effects on the breastfed child, or the effects on milk production. Human IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for HEMLIBRA and any potential adverse effects on the breastfed child from HEMLIBRA or from the underlying maternal condition.</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Females and Males of Reproductive Potential</strong></p></li></ul><p dir="ltr"><strong>Contraception</strong></p><p dir="ltr"><strong>Women of childbearing potential should use contraception while receiving HEMLIBRA.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>There is no evidence that treatment with HEMLIBRA results in an increase in adverse reactions that might lead to the impairment of the ability to drive and use machines.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>The following serious adverse reactions are described elsewhere in the labeling:</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Thrombotic Microangiopathy Associated with HEMLIBRA and aPCC [see section 4.4 Special warnings and precautions for use].</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Thromboembolism Associated with HEMLIBRA and aPCC [see section 4.4 Special warnings and precautions for use].</strong></p></li></ul><ul><li dir="ltr"><p dir="ltr"><strong>Clinical Trials Experience</strong></p></li></ul><p dir="ltr"><strong>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</strong></p><p dir="ltr"><strong>The following adverse reactions are based on pooled data from two randomized trials in adult and adolescent patients (HAVEN 1 and HAVEN 3), one single-arm trial in adult and adolescent patients (HAVEN 4), one single-arm trial in pediatric patients (HAVEN 2), and one dose-finding trial, in which a total of 391 male patients with hemophilia&nbsp;A received at least one dose of HEMLIBRA as routine prophylaxis. Two hundred eighty-one patients (72%) were adults (18 years and older), 50 (13%) were adolescents (12 years up to less than&nbsp;18 years), 55 (14%) were children (2 years up to less than&nbsp;12 years), and five (1%) were infants (1 month up to less than 2 years).&nbsp; The median duration of exposure across the studies was 34.1 weeks (0.1 to 224.4 weeks).</strong></p><p dir="ltr"><strong>The most frequently reported adverse reactions observed in &ge;&nbsp;10% of patients treated with HEMLIBRA were injection site reactions, headache, and arthralgia.</strong></p><p dir="ltr"><strong>Four patients (1%) in the clinical trials receiving HEMLIBRA prophylaxis withdrew from treatment due to adverse reactions, which were thrombotic microangiopathy, skin necrosis and superficial thrombophlebitis, headache, and injection site reaction.</strong></p><p dir="ltr"><strong>One patient withdrew from treatment after developing an anti-emicizumab-kxwh neutralizing antibody associated with loss of efficacy [see section 4.8 Undesirable effects].</strong></p><p dir="ltr"><strong>Adverse reactions observed in patients who received HEMLIBRA are shown in Table 2.</strong></p><p dir="ltr"><strong>Table&nbsp;2 Adverse Reactions Reported in &ge; 5% of Patients from Pooled Clinical Trials with HEMLIBRA</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Body System</strong></p></td><td><p dir="ltr"><strong>Adverse Reaction</strong></p></td><td><p dir="ltr"><strong>Number of Patients</strong></p><p dir="ltr"><strong>n (%)</strong></p><p dir="ltr"><strong>(N = 391)</strong></p></td></tr><tr><td rowspan="2"><p dir="ltr"><strong>General Disorders and Administration Site Conditions</strong></p></td><td><p dir="ltr"><strong>Injection site reaction*</strong></p></td><td><p dir="ltr"><strong>85 (22%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pyrexia</strong></p></td><td><p dir="ltr"><strong>23 (6%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Nervous System Disorders</strong></p></td><td><p dir="ltr"><strong>Headache</strong></p></td><td><p dir="ltr"><strong>57 (15%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Gastrointestinal Disorders</strong></p></td><td><p dir="ltr"><strong>Diarrhea</strong></p></td><td><p dir="ltr"><strong>22 (6%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td><p dir="ltr"><strong>Arthralgia</strong></p></td><td><p dir="ltr"><strong>59 (15%)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>* Includes injection site bruising, injection site discomfort, injection site erythema, injection site hematoma, injection site induration, injection site pain, injection site pruritus, injection site rash, injection site reaction, injection site swelling, injection site urticarial, and injection site warmth.&nbsp;&nbsp;</strong></p><p><br /><br />&nbsp;</p><p dir="ltr"><strong>Characterization of aPCC treatment in pooled clinical trials</strong></p><p dir="ltr"><strong>There were 130 instances of aPCC treatment in 37 patients, of which 13 instances (10%)&nbsp; consisted of on average a cumulative amount of &gt;100 U/kg/24 hours of aPCC for 24 hours or more; two of the 13 were associated with thrombotic events and three of the 13 were associated with TMA (Table 3). No TMA or thrombotic events were associated with the remaining instances of aPCC treatment.</strong></p><p dir="ltr"><strong>Table&nbsp;3 Characterization of aPCC Treatment* in Pooled Clinical Trials</strong></p><table><tbody><tr><td rowspan="2"><p dir="ltr"><strong>Duration of aPCC treatment&nbsp;</strong></p></td><td colspan="3"><p dir="ltr"><strong>Average cumulative amount of aPCC over 24 hours (U/kg/24&nbsp;hours)</strong></p></td></tr><tr><td><p dir="ltr"><strong>&lt; 50</strong></p></td><td><p dir="ltr"><strong>50 &ndash; 100</strong></p></td><td><p dir="ltr"><strong>&gt; 100</strong></p></td></tr><tr><td><p dir="ltr"><strong>&lt; 24 hours</strong></p></td><td><p dir="ltr"><strong>11</strong></p></td><td><p dir="ltr"><strong>76</strong></p></td><td><p dir="ltr"><strong>18</strong></p></td></tr><tr><td><p dir="ltr"><strong>24 &ndash; 48 hours</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>6</strong></p></td><td><p dir="ltr"><strong>3a</strong></p></td></tr><tr><td><p dir="ltr"><strong>&gt; 48 hours</strong></p></td><td><p dir="ltr"><strong>1</strong></p></td><td><p dir="ltr"><strong>5</strong></p></td><td><p dir="ltr"><strong>10a,b,b,b</strong></p></td></tr></tbody></table><p dir="ltr"><strong>* An instance of aPCC treatment is defined as all doses of aPCC received by a patient, for any reason, until there was a 36-hour treatment-free break.&nbsp;</strong></p><p dir="ltr"><strong>a Thrombotic event.</strong></p><p dir="ltr"><strong>b Thrombotic microangiopathy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Injection Site Reactions</strong></p><p dir="ltr"><strong>In total, 85 patients (22%) reported injection site reactions (ISRs). All ISRs observed in HEMLIBRA clinical trials were reported as mild to moderate intensity and 93% resolved without treatment. The commonly reported ISR symptoms were injection site erythema (11%), injection site pain (4%), and injection site pruritus (4%).&nbsp;</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>Other Less Common (&lt;1%) Reactions</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Rhabdomyolysis</strong></p></li></ul><p dir="ltr"><strong>Rhabdomyolysis was reported in two adult patients with asymptomatic elevations in serum creatine kinase without associated renal or musculoskeletal symptoms. In both instances, the event occurred following an increase in physical activity.</strong></p><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>Immunogenicity</strong></p></li></ul><p dir="ltr"><strong>As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to emicizumab-kxwh in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.</strong></p><p dir="ltr"><strong>The immunogenicity of HEMLIBRA was evaluated using an enzyme-linked immunosorbent assay (ELISA) or an electrochemiluminescence (ECL) assay. In the dose-finding trial (n = 18), four patients tested positive for anti-emicizumab-kxwh antibodies. In the pooled HAVEN clinical trials, 3.5% of patients (14/398) tested positive for anti-emicizumab-kxwh antibodies and &lt;1% of patients (3/398) developed anti-emicizumab-kxwh antibodies with neutralizing potential (based on declining pharmacokinetics). One patient from HAVEN 2, who developed an anti-emicizumab-kxwh neutralizing antibody, experienced loss of efficacy after 5 weeks of treatment.</strong></p><p dir="ltr"><strong>There was no clinically apparent impact of the presence of anti-emicizumab-kxwh antibodies on safety.&nbsp;</strong></p><p dir="ltr"><strong>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</strong></p><p dir="ltr"><strong>To report any side effect(s):</strong></p><table><tbody><tr><td><ul><li dir="ltr"><p dir="ltr"><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p></li></ul><ul><li dir="ltr"><p dir="ltr"><strong>Fax: +966-11-205-7662</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>SFDA call center: 19999</strong></p></li><li dir="ltr"><p dir="ltr"><strong>E-mail: npc.drug@sfda.gov.sa&nbsp;</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Website: www.sfda.gov.sa/npc</strong></p></li></ul></td></tr></tbody></table><p dir="ltr"><strong>&bull;&nbsp; &nbsp; Saudi Arabia:</strong></p><p><br /><br /><br />&nbsp;</p><p dir="ltr"><strong>&bull;&nbsp; &nbsp; Other GCC States:</strong></p><table><tbody><tr><td><ul><li dir="ltr"><p dir="ltr"><strong>Please contact the relevant competent authority.</strong></p></li></ul></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>There is limited experience with overdose of HEMLIBRA. Accidental overdose may result in hypercoagulability.</strong></p><p dir="ltr"><strong>Patients who receive an accidental overdose should immediately contact their physician and be monitored closely.&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>5.1 Pharmacodynamic properties</strong></p><p dir="ltr"><strong>Pharmacotherapeutic group: Other systemic hemostatics, ATC code: B02BX06.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mechanism of Action</strong></p><p dir="ltr"><strong>HEMLIBRA bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacodynamics</strong></p><p dir="ltr"><strong>Hemophilia A is an X-linked hereditary disorder of blood coagulation due to a deficiency of functional FVIII and results in bleeding into joints, muscles or internal organs, either spontaneously or as result of accidental or surgical trauma.&nbsp; Prophylactic therapy with HEMLIBRA shortens the aPTT and increases the reported FVIII activity (using a chromogenic assay with human coagulation factors).&nbsp; These two pharmacodynamic markers do not reflect the true hemostatic effect of emicizumab in vivo (aPTT is overly shortened and reported FVIII activity may be overestimated) but provide a relative indication of the pro-coagulant effect of emicizumab.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical efficacy and safety (Clinical studies)</strong></p><p><strong>Hemophilia A without FVIII Inhibitors</strong></p><p dir="ltr"><strong>The efficacy of HEMLIBRA for routine prophylaxis in patients with hemophilia&nbsp;A without FVIII inhibitors was evaluated in two clinical trials [adult and adolescent studies (HAVEN 3 and HAVEN 4)].</strong></p><p>&nbsp;</p><p dir="ltr"><strong>HAVEN 3 (Adult and Adolescent Patients)</strong></p><p dir="ltr"><strong>The HAVEN 3 study (NCT02847637) was a randomized, multicenter, open-label, clinical trial in 152 adult and adolescent males (aged &ge; 12 years and &ge;&nbsp;40&nbsp;kg) with hemophilia&nbsp;A without FVIII inhibitors who previously received either episodic (on demand) or prophylactic treatment with FVIII. Patients received HEMLIBRA prophylaxis, 3&nbsp;mg/kg once weekly for the first 4&nbsp;weeks followed by either 1.5&nbsp;mg/kg once every week [Arms A and D] or 3&nbsp;mg/kg once every two&nbsp;weeks [Arm B] thereafter, or no prophylaxis (Arm C). Patients in Arm C could switch to HEMLIBRA prophylaxis (3&nbsp;mg/kg once every two weeks) after completing at least 24&nbsp;weeks without prophylaxis. For Arms A and B, dose up-titration to 3&nbsp;mg/kg once every week was allowed after 24 weeks on HEMLIBRA prophylaxis for patients who experienced two or more qualified bleeds (i.e., spontaneous and clinically significant bleeds occurring at steady state). For Arm D patients, dose up-titration was allowed after the second qualifying bleed. During the study, five patients underwent up-titration of their maintenance dose; however, this study was not designed to investigate the 3 mg/kg once every week dosing regimen.</strong></p><p dir="ltr"><strong>Eighty-nine patients previously treated with episodic (on demand) FVIII were randomized in a 2:2:1 ratio to receive HEMLIBRA prophylaxis 1.5 mg/kg once every week (Arm&nbsp;A), 3 mg/kg once every two weeks (Arm B), or no prophylaxis (Arm&nbsp;C), with stratification by prior 24-week bleed rate (&lt;&nbsp;9 or &ge;&nbsp;9). Sixty-three patients previously treated with prophylactic FVIII were enrolled into Arm&nbsp;D to receive HEMLIBRA prophylaxis (1.5&nbsp;mg/kg once every week).</strong></p><p dir="ltr"><strong>Efficacy was evaluated after a minimum of 24 weeks of follow-up based on the bleed rate for bleeds requiring treatment with coagulation factors among patients previously treated with episodic (on-demand) FVIII who were randomized to HEMLIBRA prophylaxis 1.5 mg/kg once every week (Arm A) or 3 mg/kg once every two weeks (Arm B) compared with those receiving no prophylaxis (Arm C). The study also evaluated the randomized comparison of Arms&nbsp;A and C and Arms B and C for the efficacy of HEMLIBRA prophylaxis in reducing the number of all bleeds, spontaneous bleeds, joint bleeds, and target joint bleeds.</strong></p><p dir="ltr"><strong>The efficacy of HEMLIBRA prophylaxis compared with previous prophylactic FVIII was also evaluated in patients who had participated in a non-interventional study (NIS) prior to enrollment (Arm D). Only patients from the NIS were included in this comparison, because bleed and treatment data were collected with the same level of granularity as that used in HAVEN 3.</strong></p><p dir="ltr"><strong>The efficacy results of HEMLIBRA prophylaxis (1.5 mg/kg once every week and 3&nbsp;mg/kg once every two weeks) compared with no prophylaxis with respect to rate of treated bleeds, all bleeds, treated spontaneous bleeds, treated joint bleeds, and treated target joint bleeds are shown in Table 4.</strong></p><p dir="ltr"><strong>Table&nbsp;4 Annualized Bleed Rate with HEMLIBRA Prophylaxis versus No Prophylaxis in Patients&nbsp;&ge;&nbsp;12 Years of Age without Factor VIII Inhibitors&nbsp;</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Endpoint</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA&nbsp;</strong></p><p dir="ltr"><strong>1.5 mg/kg once every week (N&nbsp;=&nbsp;36)</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA&nbsp;</strong></p><p dir="ltr"><strong>3 mg/kg once every two weeks (N&nbsp;=&nbsp;35)</strong></p></td><td><p dir="ltr"><strong>No Prophylaxis</strong></p><p dir="ltr"><strong>(N&nbsp;=&nbsp;18)</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Treated Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>1.5 (0.9, 2.5)</strong></p></td><td><p dir="ltr"><strong>1.3 (0.8, 2.3)</strong></p></td><td><p dir="ltr"><strong>38.2 (22.9, 63.8)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td><p dir="ltr"><strong>96% (92.5%, 98%)</strong></p><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td><td><p dir="ltr"><strong>97% (93.4%, 98.3%)</strong></p><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>55.6 (38.1, 72.1)</strong></p></td><td><p dir="ltr"><strong>60 (42.1, 76.1)</strong></p></td><td><p dir="ltr"><strong>0 (0, 18.5)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 2.5)</strong></p></td><td><p dir="ltr"><strong>0 (0, 1.9)</strong></p></td><td><p dir="ltr"><strong>40.4 (25.3, 56.7)</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>All Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>2.5 (1.6, 3.9)</strong></p></td><td><p dir="ltr"><strong>2.6 (1.6, 4.3)</strong></p></td><td><p dir="ltr"><strong>47.6 (28.5, 79.6)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td><p dir="ltr"><strong>95% (90.1%, 97%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>94% (89.7%, 97%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>50 (32.9, 67.1)</strong></p></td><td><p dir="ltr"><strong>40 (23.9, 57.9)</strong></p></td><td><p dir="ltr"><strong>0 (0, 18.5)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0.6 (0, 3.9)</strong></p></td><td><p dir="ltr"><strong>1.6 (0, 4)</strong></p></td><td><p dir="ltr"><strong>46.9 (26.1, 73.9)</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Treated Spontaneous Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>1.0 (0.5, 1.9)</strong></p></td><td><p dir="ltr"><strong>0.3 (0.1, 0.8)</strong></p></td><td><p dir="ltr"><strong>15.6 (7.6, 31.9)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td><p dir="ltr"><strong>94% (84.9%, 97.5%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>98% (94.4%, 99.4%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>66.7 (49.0, 81.4)</strong></p></td><td><p dir="ltr"><strong>88.6 (73.3, 96.8)</strong></p></td><td><p dir="ltr"><strong>22.2 (6.4, 47.6)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 1.3)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>10.8 (2.1, 26)</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Treated Joint Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>1.1 (0.6, 1.9)</strong></p></td><td><p dir="ltr"><strong>0.9 (0.4, 1.7)</strong></p></td><td><p dir="ltr"><strong>26.5 (14.7, 47.8)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td><p dir="ltr"><strong>96% (91.5%, 98.1%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>97% (93%, 98.5%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>58.3 (40.8, 74.5)</strong></p></td><td><p dir="ltr"><strong>74.3 (56.7, 87.5)</strong></p></td><td><p dir="ltr"><strong>0 (0, 18.5)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 1.9)</strong></p></td><td><p dir="ltr"><strong>0 (0, 1.3)&nbsp;</strong></p></td><td><p dir="ltr"><strong>21.3 (14.5, 41.3)</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Treated Target Joint Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>0.6 (0.3, 1.4)</strong></p></td><td><p dir="ltr"><strong>0.7 (0.3, 1.6)</strong></p></td><td><p dir="ltr"><strong>13 (5.2, 32.3)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td><p dir="ltr"><strong>95% (85.7%, 98.4%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>95% (85.3%, 98.2%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>69.4 (51.9, 83.7)</strong></p></td><td><p dir="ltr"><strong>77.1 (59.9, 89.6)</strong></p></td><td><p dir="ltr"><strong>27.8 (9.7, 53.5)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 1.4)&nbsp;</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)&nbsp;</strong></p></td><td><p dir="ltr"><strong>12.8 (0, 39.1)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th percentile.</strong></p><p dir="ltr"><strong>a Based on negative binomial regression model.</strong></p><p dir="ltr"><strong>In the HAVEN 3 intra-patient analysis, HEMLIBRA prophylaxis resulted in a statistically significant (p &lt; 0.0001) reduction (68%) in bleed rate for treated bleeds compared with previous FVIII prophylaxis collected in the NIS prior to enrollment (see Table 5).</strong></p><p dir="ltr"><strong>Table&nbsp;5 Intra-Patient Comparison of Annualized Bleed Rate with HEMLIBRA Prophylaxis versus Previous FVIII Prophylaxis</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Endpoint</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA&nbsp;</strong></p><p dir="ltr"><strong>1.5 mg/kg once every week</strong></p><p dir="ltr"><strong>(N&nbsp;=&nbsp;48)</strong></p></td><td><p dir="ltr"><strong>Previous FVIII Prophylaxis</strong></p><p dir="ltr"><strong>(N&nbsp;=&nbsp;48)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median Observation Period (weeks)</strong></p></td><td><p dir="ltr"><strong>33.7</strong></p></td><td><p dir="ltr"><strong>30.1</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Treated Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>1.5 (1, 2.3)&nbsp;</strong></p></td><td><p dir="ltr"><strong>4.8 (3.2, 7.1)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td colspan="2"><p dir="ltr"><strong>68% (48.6%, 80.5%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>54.2 (39.2, 68.6)&nbsp;</strong></p></td><td><p dir="ltr"><strong>39.6 (25.8, 54.7)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 2.1)&nbsp;</strong></p></td><td><p dir="ltr"><strong>1.8 (0, 7.6)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th percentile.</strong></p><p dir="ltr"><strong>a Based on negative binomial regression model.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>HAVEN 4 (Adult and Adolescent Patients)</strong></p><p dir="ltr"><strong>The HAVEN 4 study (NCT03020160) was a single-arm, multicenter, open-label, clinical trial in 41 adult and adolescent males (aged &ge; 12 years and &ge; 40 kg) with hemophilia A with or without FVIII inhibitors who previously received either episodic (on demand) or prophylactic treatment with FVIII or bypassing agents. Patients received HEMLIBRA prophylaxis at 3&nbsp;mg/kg once weekly for the first 4&nbsp;weeks followed by 6&nbsp;mg/kg once every four weeks thereafter.&nbsp;</strong></p><p dir="ltr"><strong>Efficacy was evaluated in a subgroup of 36 patients with hemophilia A without FVIII inhibitors based on the bleed rate for bleeds requiring treatment with coagulation factors. The study also evaluated the efficacy of HEMLIBRA prophylaxis on all bleeds, treated spontaneous bleeds, treated joint bleeds, and treated target joint bleeds.</strong></p><p dir="ltr"><strong>The efficacy results of HEMLIBRA prophylaxis 6 mg/kg once every four weeks with respect to rate of treated bleeds, all bleeds, treated spontaneous bleeds, treated joint bleeds, and treated target joint bleeds are shown in Table 6. The median observation time was 25.6 weeks (range 24.1 &ndash; 29.4 weeks).</strong></p><p dir="ltr"><strong>Table 6 Annualized Bleed Rate with HEMLIBRA Prophylaxis 6 mg/kg Once Every Four Weeks in Patients &ge;&nbsp;12 Years of Age without Factor VIII Inhibitors</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Endpoint</strong></p></td><td><p dir="ltr"><strong>ABRa (95% CI)</strong></p><p dir="ltr"><strong>N = 36</strong></p></td><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p><p dir="ltr"><strong>N = 36</strong></p></td><td><p dir="ltr"><strong>% Zero Bleeds (95% CI)</strong></p><p dir="ltr"><strong>N = 36</strong></p></td></tr><tr><td><p dir="ltr"><strong>Treated Bleeds</strong></p></td><td><p dir="ltr"><strong>2.6 (1.5, 4.7)</strong></p></td><td><p dir="ltr"><strong>0 (0, 2.1)</strong></p></td><td><p dir="ltr"><strong>52.8 (35.5, 69.6)</strong></p></td></tr><tr><td><p dir="ltr"><strong>All Bleeds</strong></p></td><td><p dir="ltr"><strong>4.8 (3.2, 7.1)</strong></p></td><td><p dir="ltr"><strong>2.1 (0, 6.1)</strong></p></td><td><p dir="ltr"><strong>27.8 (14.2, 45.2)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Treated Spontaneous Bleeds</strong></p></td><td><p dir="ltr"><strong>0.6 (0.2, 1.6)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>83.3 (67.2, 93.6)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Treated Joint Bleeds</strong></p></td><td><p dir="ltr"><strong>1.8 (0.8, 4)</strong></p></td><td><p dir="ltr"><strong>0 (0, 1.9)</strong></p></td><td><p dir="ltr"><strong>69.4 (51.9, 83.7)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Treated Target Joint Bleeds</strong></p></td><td><p dir="ltr"><strong>1.1 (0.4, 3.7)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>83.3 (67.2, 93.6)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th percentile.</strong></p><p dir="ltr"><strong>a Based on negative binomial regression model.</strong></p><p>&nbsp;</p><p><strong>Hemophilia A with FVIII Inhibitors</strong></p><p dir="ltr"><strong>The efficacy of HEMLIBRA for routine prophylaxis in patients with hemophilia&nbsp;A with FVIII inhibitors was evaluated in three clinical trials [adult and adolescent studies (HAVEN 1 and HAVEN 4) and a pediatric study (HAVEN 2)].</strong></p><p>&nbsp;</p><p dir="ltr"><strong>HAVEN 1 (Adult and Adolescent Patients)</strong></p><p dir="ltr"><strong>The HAVEN 1 study (NCT02622321) was a randomized, multicenter, open-label, clinical trial in 109 adult and adolescent males (aged &ge; 12 years and &ge; 40 kg) with hemophilia&nbsp;A with FVIII inhibitors who previously received either episodic (on-demand) or prophylactic treatment with bypassing agents. Patients received HEMLIBRA prophylaxis (Arms A, C, and D), 3&nbsp;mg/kg once weekly for the first 4 weeks followed by 1.5&nbsp;mg/kg once every week thereafter, or no prophylaxis (Arm&nbsp;B). Patients in Arm&nbsp;B could switch to HEMLIBRA prophylaxis after completing at least 24&nbsp;weeks without prophylaxis. Dose up-titration to 3&nbsp;mg/kg once every week was allowed after 24&nbsp;weeks on HEMLIBRA prophylaxis for patients who experienced two or more qualified bleeds (i.e., spontaneous and clinically significant bleeds occurring at steady state). During the study, two patients underwent up-titration of their maintenance dose; however, this study was not designed to investigate the 3 mg/kg once every week dosing regimen.</strong></p><p dir="ltr"><strong>Fifty-three patients previously treated with episodic (on-demand) bypassing agents were randomized in a 2:1 ratio to receive HEMLIBRA prophylaxis (Arm&nbsp;A) or no prophylaxis (Arm&nbsp;B), with stratification by prior 24-week bleed rate (&lt;&nbsp;9 or &ge;&nbsp;9). Forty-nine patients previously treated with prophylactic bypassing agents were enrolled into Arm&nbsp;C to receive HEMLIBRA prophylaxis. Seven patients previously treated with episodic (on-demand) bypassing agents who had participated in the NIS prior to enrollment, but were unable to enroll into HAVEN 1 prior to the closure of Arms A and B, were enrolled into Arm&nbsp;D to receive HEMLIBRA prophylaxis.</strong></p><p dir="ltr"><strong>Efficacy was evaluated after a minimum of 24 weeks of follow-up based on the bleed rate for bleeds requiring treatment with coagulation factors among patients previously treated with episodic bypassing agents who were randomized to HEMLIBRA prophylaxis (Arm A) compared with those receiving no prophylaxis (Arm B). The study also evaluated the randomized comparison of Arms&nbsp;A and B for the efficacy of HEMLIBRA prophylaxis in reducing the number of all bleeds, spontaneous bleeds, joint bleeds, and target joint bleeds, as well as patient-reported symptoms and physical functioning.</strong></p><p dir="ltr"><strong>The efficacy of HEMLIBRA prophylaxis compared with previous prophylactic bypassing agents was also evaluated in patients who had participated in the NIS prior to enrollment (Arm C). Only patients from the NIS were included in this comparison, because bleed and treatment data were collected with the same level of granularity as that used in HAVEN 1.</strong></p><p dir="ltr"><strong>The efficacy results of HEMLIBRA prophylaxis 1.5 mg/kg once every week compared with no prophylaxis with respect to rate of treated bleeds, all bleeds, treated spontaneous bleeds, treated joint bleeds, and treated target joint bleeds are shown in Table 7.</strong></p><p dir="ltr"><strong>Table&nbsp;7 Annualized Bleed Rate with HEMLIBRA Prophylaxis versus No Prophylaxis in Patients&nbsp;&ge;&nbsp;12 Years of Age with Factor VIII Inhibitors&nbsp;</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Endpoint</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA&nbsp;</strong></p><p dir="ltr"><strong>1.5 mg/kg once every week (N&nbsp;=&nbsp;35)</strong></p></td><td><p dir="ltr"><strong>&nbsp; No Prophylaxis</strong></p><p dir="ltr"><strong>(N&nbsp;=&nbsp;18)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Treated Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>2.9 (1.7, 5.0)</strong></p></td><td><p dir="ltr"><strong>23.3 (12.3, 43.9)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td colspan="2"><p dir="ltr"><strong>87% (72.3%, 94.3%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>62.9 (44.9, 78.5)</strong></p></td><td><p dir="ltr"><strong>5.6 (0.1, 27.3)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 3.7)</strong></p></td><td><p dir="ltr"><strong>18.8 (13.0, 35.1)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>All Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>5.5 (3.6, 8.6)</strong></p></td><td><p dir="ltr"><strong>28.3 (16.8, 47.8)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td colspan="2"><p dir="ltr"><strong>80% (62.5%, 89.8%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>37.1 (21.5, 55.1)</strong></p></td><td><p dir="ltr"><strong>5.6 (0.1, 27.3)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>2 (0, 9.9)</strong></p></td><td><p dir="ltr"><strong>30.2 (18.3, 39.4)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Treated Spontaneous Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>1.3 (0.7, 2.2)</strong></p></td><td><p dir="ltr"><strong>16.8 (9.9, 28.3)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td colspan="2"><p dir="ltr"><strong>92% (84.6%, 96.3%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>68.6 (50.7, 83.1)</strong></p></td><td><p dir="ltr"><strong>11.1 (1.4, 34.7)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 3.3)</strong></p></td><td><p dir="ltr"><strong>15.2 (6.6, 30.4)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Treated Joint Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>0.8 (0.3, 2.2)</strong></p></td><td><p dir="ltr"><strong>6.7 (2.0, 22.4)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td colspan="2"><p dir="ltr"><strong>89% (48%, 97.5%)</strong></p><p dir="ltr"><strong>0.0050</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>85.7 (69.7, 95.2)</strong></p></td><td><p dir="ltr"><strong>50.0 (26.0, 74.0)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>1 (0, 14.4)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Treated Target Joint Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>0.1 (0.03, 0.6)</strong></p></td><td><p dir="ltr"><strong>3.0 (1.0, 9.1)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td colspan="2"><p dir="ltr"><strong>95% (77.3%, 99.1%)</strong></p><p dir="ltr"><strong>0.0002</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>94.3 (80.8, 99.3)</strong></p></td><td><p dir="ltr"><strong>50.0 (26.0, 74.0)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>1 (0, 6.5)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th percentile.</strong></p><p dir="ltr"><strong>a Based on negative binomial regression model.</strong></p><p dir="ltr"><strong>Descriptive analyses were conducted to assess HEMLIBRA prophylaxis once every week using 12-week treatment intervals up to Week 72. The descriptive mean ABRs for treated bleeds are shown in Table 8.</strong></p><p dir="ltr"><strong>Table&nbsp;8 Annualized Bleed Rate with HEMLIBRA Prophylaxis Once Every Week per 12-Week Intervals in Patients &ge;&nbsp;12 Years of Age with Factor VIII Inhibitors</strong></p><table><tbody><tr><td rowspan="2"><p dir="ltr"><strong>Endpoint</strong></p></td><td colspan="6"><p dir="ltr"><strong>Time Interval (Weeks)</strong></p></td></tr><tr><td><p dir="ltr"><strong>1 &ndash; 12</strong></p><p dir="ltr"><strong>(N = 109)</strong></p></td><td><p dir="ltr"><strong>13 &ndash; 24</strong></p><p dir="ltr"><strong>(N = 108)</strong></p></td><td><p dir="ltr"><strong>25 &ndash; 36</strong></p><p dir="ltr"><strong>(N = 93)</strong></p></td><td><p dir="ltr"><strong>37 &ndash; 48</strong></p><p dir="ltr"><strong>(N = 93)</strong></p></td><td><p dir="ltr"><strong>49 &ndash; 60</strong></p><p dir="ltr"><strong>(N = 57)</strong></p></td><td><p dir="ltr"><strong>61 &ndash; 72</strong></p><p dir="ltr"><strong>(N = 42)</strong></p></td></tr><tr><td colspan="7"><p dir="ltr"><strong>Treated Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>Mean ABR (95% CI)</strong></p></td><td><p dir="ltr"><strong>3.9&nbsp;</strong></p><p dir="ltr"><strong>(1.1, 10.2)</strong></p></td><td><p dir="ltr"><strong>2.2&nbsp;</strong></p><p dir="ltr"><strong>(0.3, 7.6)</strong></p></td><td><p dir="ltr"><strong>0.9&nbsp;</strong></p><p dir="ltr"><strong>(0, 5.5)</strong></p></td><td><p dir="ltr"><strong>0.4&nbsp;</strong></p><p dir="ltr"><strong>(0, 4.4)</strong></p></td><td><p dir="ltr"><strong>0.5&nbsp;</strong></p><p dir="ltr"><strong>(0, 4.7)</strong></p></td><td><p dir="ltr"><strong>0.6&nbsp;</strong></p><p dir="ltr"><strong>(0, 4.9)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ABR = annualized bleed rate; CI = confidence interval based on Poisson distribution; N = number of patients who contributed data for analyses at each time interval.</strong></p><p dir="ltr"><strong>In the HAVEN 1 intra-patient analysis, HEMLIBRA prophylaxis resulted in a statistically significant (p&nbsp;=&nbsp;0.0003) reduction (79%) in bleed rate for treated bleeds compared with previous bypassing agent prophylaxis collected in the NIS prior to enrollment (Table 9).</strong></p><p dir="ltr"><strong>Table&nbsp;9 Intra-Patient Comparison of Annualized Bleed Rate with HEMLIBRA Prophylaxis versus Previous Bypassing Agent Prophylaxis</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Endpoint</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA&nbsp;</strong></p><p dir="ltr"><strong>1.5 mg/kg once every week (N&nbsp;=&nbsp;24)</strong></p></td><td><p dir="ltr"><strong>Previous Bypassing Agent Prophylaxis (N&nbsp;=&nbsp;24)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median Observation Period (weeks)</strong></p></td><td><p dir="ltr"><strong>30.1</strong></p></td><td><p dir="ltr"><strong>32.1</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Treated Bleeds</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR (95% CI) a</strong></p></td><td><p dir="ltr"><strong>3.3 (1.3, 8.1)</strong></p></td><td><p dir="ltr"><strong>15.7 (11.1, 22.3)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction (95% CI)&nbsp;</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td colspan="2"><p dir="ltr"><strong>79% (51.4%, 91.1%)</strong></p><p dir="ltr"><strong>0.0003</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>70.8 (48.9, 87.4)</strong></p></td><td><p dir="ltr"><strong>12.5 (2.7, 32.4)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0 (0, 2.2)</strong></p></td><td><p dir="ltr"><strong>12 (5.7, 24.2)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th percentile.</strong></p><p dir="ltr"><strong>a Based on negative binomial regression model.</strong></p><p dir="ltr"><strong>The HAVEN 1 study evaluated patient-reported hemophilia-related symptoms (painful swellings and presence of joint pain) and physical functioning (pain with movement and difficulty walking far) using the Physical Health Score of the Haemophilia-specific Quality of Life (Haem-A-QoL) questionnaire for patients&nbsp;&ge;&nbsp;18 years of age. The HEMLIBRA prophylaxis arm (Arm&nbsp;A) showed an improvement compared with the no prophylaxis arm (Arm&nbsp;B) in the Haem-A-QoL Physical Health Subscale score at the Week&nbsp;25 assessment (Table 10). The improvement in the Physical Health Score was further supported by the Total Score as measured by the Haem-A-QoL at Week 25.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table&nbsp;10 Change in Haem-A-QoL Physical Health Score with HEMLIBRA Prophylaxis versus No Prophylaxis in Patients (&ge;&nbsp;18 Years of Age) with Factor VIII Inhibitors at Week 25</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Haem-A-QoL Scores at Week 25</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA&nbsp;</strong></p><p dir="ltr"><strong>1.5 mg/kg once every week (N&nbsp;=&nbsp;25a)</strong></p></td><td><p dir="ltr"><strong>No Prophylaxis</strong></p><p dir="ltr"><strong>(N&nbsp;=&nbsp;14a)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Physical Health Score (range 0 to 100)b</strong></p></td></tr><tr><td><p dir="ltr"><strong>Adjusted mean c</strong></p></td><td><p dir="ltr"><strong>32.6</strong></p></td><td><p dir="ltr"><strong>54.2</strong></p></td></tr><tr><td><p dir="ltr"><strong>Difference in adjusted means (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>21.6 (7.9, 35.2)</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.0029</strong></p></td></tr></tbody></table><p dir="ltr"><strong>a Number of patients&nbsp;&ge;&nbsp;18 years who completed the Haem-A-QoL questionnaire.</strong></p><p dir="ltr"><strong>b Lower scores are reflective of better functioning.</strong></p><p dir="ltr"><strong>c Adjusted for baseline, and baseline by treatment group interaction.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>HAVEN 2 (Pediatric Patients)</strong></p><p dir="ltr"><strong>The HAVEN 2 study (NCT02795767) was a single-arm, multicenter, open-label, clinical trial in pediatric males (age&nbsp;&lt;&nbsp;12 years, or 12&nbsp;&minus;&nbsp;17 years who weigh&nbsp;&lt;&nbsp;40&nbsp;kg) with hemophilia&nbsp;A with FVIII inhibitors. Patients received HEMLIBRA prophylaxis at 3&nbsp;mg/kg once weekly for the first 4 weeks followed by 1.5&nbsp;mg/kg once every week thereafter.</strong></p><p dir="ltr"><strong>The study evaluated the efficacy of HEMLIBRA prophylaxis, including the efficacy of HEMLIBRA prophylaxis compared with previous episodic (on-demand) and prophylactic bypassing agent treatment in patients who had participated in a non-interventional study (NIS) prior to enrollment (intra-patient analysis).</strong></p><p dir="ltr"><strong>At the time of the interim analysis, efficacy was evaluated in 59 pediatric patients who were &lt;&nbsp;12&nbsp;years of age and had been receiving HEMLIBRA prophylaxis for at least 12 weeks, including 38 patients age 6 to&nbsp;&lt;&nbsp;12 years, 17 patients age 2 to&nbsp;&lt;&nbsp;6 years, and four patients age &lt; 2 years.</strong></p><p dir="ltr"><strong>Annualized bleed rate (ABR) and percent of patients with zero bleeds were calculated for 59 patients (Table 11). The median observation time for these patients was 29.6 weeks (range 18.4 &ndash; 63 weeks).&nbsp;</strong></p><p dir="ltr"><strong>Table&nbsp;11 Annualized Bleed Rate with HEMLIBRA Prophylaxis 1.5 mg/kg Once Every Week in Pediatric Patients&nbsp;&lt;&nbsp;12 Years of Age with Factor VIII Inhibitors (Interim Analysis)</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Endpoint</strong></p></td><td><p dir="ltr"><strong>ABRa (95% CI)</strong></p><p dir="ltr"><strong>N = 59</strong></p></td><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p><p dir="ltr"><strong>N = 59</strong></p></td><td><p dir="ltr"><strong>% Zero Bleeds (95% CI)</strong></p><p dir="ltr"><strong>N = 59</strong></p></td></tr><tr><td><p dir="ltr"><strong>Treated Bleeds</strong></p></td><td><p dir="ltr"><strong>0.3 (0.1, 0.5)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>86.4 (75, 94)</strong></p></td></tr><tr><td><p dir="ltr"><strong>All Bleeds</strong></p></td><td><p dir="ltr"><strong>3.8 (2.2, 6.5)</strong></p></td><td><p dir="ltr"><strong>0 (0, 3.4)</strong></p></td><td><p dir="ltr"><strong>55.9 (42.4, 68.8)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Treated Spontaneous Bleeds</strong></p></td><td><p dir="ltr"><strong>0 (0, 0.2)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>98.3 (90.9, 100)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Treated Joint Bleeds</strong></p></td><td><p dir="ltr"><strong>0.2 (0.1, 0.4)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>89.8 (79.2, 96.2)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Treated Target Joint Bleeds</strong></p></td><td><p dir="ltr"><strong>0.1 (0, 0.7)</strong></p></td><td><p dir="ltr"><strong>0 (0, 0)</strong></p></td><td><p dir="ltr"><strong>96.6 (88.3, 99.6)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th percentile.</strong></p><p dir="ltr"><strong>a Based on negative binomial regression model.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the intra-patient analysis, 18 pediatric patients who had participated in the NIS had an ABR for treated bleeds of 19.8 (95% CI [15.3, 25.7]) on previous bypassing agent treatment (prophylactic treatment in 15 patients and on-demand treatment for 3 patients). HEMLIBRA prophylaxis resulted in an ABR for treated bleeds of 0.4 (95% CI [0.2, 0.9]) based on negative binomial regression, corresponding to a 98% reduction in bleed rate. On HEMLIBRA prophylaxis, 14 patients (77.8%) had zero treated bleeds.&nbsp;</strong></p><p dir="ltr"><strong>The HAVEN 2 study evaluated patient-reported hemophilia-related symptoms (painful swellings and presence of joint pain) and physical functioning (pain with movement) using the Physical Health Score of the Hemophilia-specific Quality of Life Short Form (Haemo-QoL-SF) questionnaire for patients &ge; 8 to &lt; 12 years of age. HEMLIBRA prophylaxis showed improvement from baseline in the Haemo-QoL-SF Physical Health Subscale score at the Week 25 assessment.</strong></p><p dir="ltr"><strong>HAVEN 4 (Adult and Adolescent Patients)</strong></p><p dir="ltr"><strong>The HAVEN 4 study (NCT03020160) was a single-arm, multicenter, open-label, clinical trial in 41 adult and adolescent males (aged &ge; 12 years and &ge; 40 kg) with hemophilia A with or without FVIII inhibitors who previously received either episodic (on demand) or prophylactic treatment with FVIII or bypassing agents. Patients received HEMLIBRA prophylaxis at 3&nbsp;mg/kg once weekly for the first 4&nbsp;weeks followed by 6&nbsp;mg/kg once every four weeks thereafter.&nbsp;</strong></p><p dir="ltr"><strong>Efficacy was evaluated in a subgroup of 5 patients with hemophilia A with FVIII inhibitors based on the bleed rate for bleeds requiring treatment with coagulation factors. The median observation time was 26.1 weeks (range 24.4 &ndash; 28.6 weeks). HEMLIBRA prophylaxis resulted in an ABR (95% CI) for treated bleeds of 1.2 (0.1, 14.8) based on negative binomial regression. On HEMLIBRA prophylaxis, 4 patients had zero treated bleeds.</strong></p><p dir="ltr"><strong>The efficacy results of HEMLIBRA prophylaxis (1.5 mg/kg once every week, 3 mg/kg once every two weeks, and 6 mg/kg once every four weeks) with respect to rate of treated bleeds are shown in Table 12.</strong></p><p dir="ltr"><strong>Table&nbsp;12 Annualized Bleed Rate (Treated Bleeds) with HEMLIBRA Prophylaxis in Patients&nbsp;with or without Factor VIII Inhibitors</strong></p><table><tbody><tr><td rowspan="2"><p dir="ltr"><strong>Endpoint</strong></p></td><td colspan="2"><p dir="ltr"><strong>HAVEN 1</strong></p></td><td><p dir="ltr"><strong>HAVEN 2</strong></p></td><td colspan="3"><p dir="ltr"><strong>HAVEN 3</strong></p></td><td><p dir="ltr"><strong>HAVEN 4</strong></p></td></tr><tr><td><p dir="ltr"><strong>HEMLIBRA 1.5 mg/kg&nbsp;</strong></p><p dir="ltr"><strong>once every week&nbsp;</strong></p><p dir="ltr"><strong>(N = 35)</strong></p></td><td><p dir="ltr"><strong>No Prophylaxis</strong></p><p dir="ltr"><strong>(N = 18)</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA 1.5 mg/kg&nbsp;</strong></p><p dir="ltr"><strong>once every week&nbsp;</strong></p><p dir="ltr"><strong>(N = 59)</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA 1.5 mg/kg&nbsp;</strong></p><p dir="ltr"><strong>once every week&nbsp;</strong></p><p dir="ltr"><strong>(N = 36)</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA&nbsp;</strong></p><p dir="ltr"><strong>3 mg/kg&nbsp;</strong></p><p dir="ltr"><strong>once every&nbsp;</strong></p><p dir="ltr"><strong>two weeks&nbsp;</strong></p><p dir="ltr"><strong>(N = 35)</strong></p></td><td><p dir="ltr"><strong>No Prophylaxis&nbsp;</strong></p><p dir="ltr"><strong>(N = 18)</strong></p></td><td><p dir="ltr"><strong>HEMLIBRA</strong></p><p dir="ltr"><strong>6 mg/kg&nbsp;</strong></p><p dir="ltr"><strong>once every four weeks&nbsp;</strong></p><p dir="ltr"><strong>(N = 41)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median Efficacy Period (weeks)</strong></p></td><td><p dir="ltr"><strong>29.3</strong></p></td><td><p dir="ltr"><strong>24</strong></p></td><td><p dir="ltr"><strong>29.6</strong></p></td><td><p dir="ltr"><strong>29.6</strong></p></td><td><p dir="ltr"><strong>31.3</strong></p></td><td><p dir="ltr"><strong>24</strong></p></td><td><p dir="ltr"><strong>25.6</strong></p></td></tr><tr><td><p dir="ltr"><strong>ABR&nbsp;</strong></p><p dir="ltr"><strong>(95% CI) a</strong></p></td><td><p dir="ltr"><strong>2.9&nbsp;</strong></p><p dir="ltr"><strong>(1.7, 5)</strong></p></td><td><p dir="ltr"><strong>23.3&nbsp;</strong></p><p dir="ltr"><strong>(12.3, 43.9)</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p><p dir="ltr"><strong>(0.1, 0.5)</strong></p></td><td><p dir="ltr"><strong>1.5</strong></p><p dir="ltr"><strong>(0.9, 2.5)</strong></p></td><td><p dir="ltr"><strong>1.3</strong></p><p dir="ltr"><strong>(0.8, 2.3)</strong></p></td><td><p dir="ltr"><strong>38.2&nbsp;</strong></p><p dir="ltr"><strong>(22.9, 63.8)</strong></p></td><td><p dir="ltr"><strong>2.4&nbsp;</strong></p><p dir="ltr"><strong>(1.4, 4.3)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% reduction vs no prophylaxis (95% CI),&nbsp;</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td><p dir="ltr"><strong>87%&nbsp;</strong></p><p dir="ltr"><strong>(72.3%, 94.3%)</strong></p><p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td><td><p dir="ltr"><strong>96%&nbsp;</strong></p><p dir="ltr"><strong>(92.5%, 98%)</strong></p><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td><td><p dir="ltr"><strong>97%&nbsp;</strong></p><p dir="ltr"><strong>(93.4%, 98.3%)</strong></p><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 bleeds&nbsp;</strong></p><p dir="ltr"><strong>(95% CI)</strong></p></td><td><p dir="ltr"><strong>62.9&nbsp;</strong></p><p dir="ltr"><strong>(44.9, 78.5)</strong></p></td><td><p dir="ltr"><strong>5.6&nbsp;</strong></p><p dir="ltr"><strong>(0.1, 27.3)</strong></p></td><td><p dir="ltr"><strong>86.4</strong></p><p dir="ltr"><strong>(75, 94)</strong></p></td><td><p dir="ltr"><strong>55.6&nbsp;</strong></p><p dir="ltr"><strong>(38.1, 72.1)</strong></p></td><td><p dir="ltr"><strong>60</strong></p><p dir="ltr"><strong>(42.1, 76.1)</strong></p></td><td><p dir="ltr"><strong>0&nbsp;</strong></p><p dir="ltr"><strong>(0, 18.5)</strong></p></td><td><p dir="ltr"><strong>56.1</strong></p><p dir="ltr"><strong>(39.7, 71.5)</strong></p></td></tr><tr><td><p dir="ltr"><strong>% patients with 0 - 3 bleeds (95% CI)</strong></p></td><td><p dir="ltr"><strong>85.7</strong></p><p dir="ltr"><strong>(69.7, 95.2)</strong></p></td><td><p dir="ltr"><strong>11.1</strong></p><p dir="ltr"><strong>(1.4, 34.7)</strong></p></td><td><p dir="ltr"><strong>100</strong></p><p dir="ltr"><strong>(93.9, 100)</strong></p></td><td><p dir="ltr"><strong>91.7</strong></p><p dir="ltr"><strong>(77.5, 98.2)</strong></p></td><td><p dir="ltr"><strong>94.3</strong></p><p dir="ltr"><strong>(80.8, 99.3)</strong></p></td><td><p dir="ltr"><strong>5.6</strong></p><p dir="ltr"><strong>(0.1, 27.3)</strong></p></td><td><p dir="ltr"><strong>90.2</strong></p><p dir="ltr"><strong>(76.9, 97.3)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median ABR (IQR)</strong></p></td><td><p dir="ltr"><strong>0&nbsp;</strong></p><p dir="ltr"><strong>(0, 3.7)</strong></p></td><td><p dir="ltr"><strong>18.8&nbsp;</strong></p><p dir="ltr"><strong>(13, 35.1)</strong></p></td><td><p dir="ltr"><strong>0</strong></p><p dir="ltr"><strong>(0, 0)</strong></p></td><td><p dir="ltr"><strong>0</strong></p><p dir="ltr"><strong>(0, 2.5)</strong></p></td><td><p dir="ltr"><strong>0&nbsp;</strong></p><p dir="ltr"><strong>(0, 1.9)</strong></p></td><td><p dir="ltr"><strong>40.4&nbsp;</strong></p><p dir="ltr"><strong>(25.3, 56.7)</strong></p></td><td><p dir="ltr"><strong>0</strong></p><p dir="ltr"><strong>(0, 2.1)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th percentile; HAVEN 1 = adult and adolescent patients with factor VIII inhibitors; HAVEN 2 = pediatric patients with factor VIII inhibitors; HAVEN 3 = adult and adolescent patients without factor VIII inhibitors; HAVEN 4 = adult and adolescent patients with or without factor VIII inhibitors.&nbsp;</strong></p><p dir="ltr"><strong>a Based on negative binomial regression model.</strong></p><p dir="ltr"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Emicizumab-kxwh exhibited dose-proportional pharmacokinetics over a dose range of 0.3 mg/kg (0.1 times approved recommended starting dosage) to 6&nbsp;mg/kg following subcutaneous administration. Following multiple subcutaneous administrations of a loading dose of 3 mg/kg emicizumab-kxwh once weekly for the first 4 weeks in hemophilia A patients, mean (&plusmn; SD) trough plasma concentrations of 52.6&nbsp;&plusmn;&nbsp;13.6&nbsp;&mu;g/mL was achieved at Week&nbsp;5. Sustained mean (&plusmn;&nbsp;SD) plasma concentrations of emicizumab-kxwh at steady-state with the recommended maintenance doses are shown in Table 13.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 13 Mean (&plusmn; SD) Steady-State Concentrations after emicizumab-kxwh Loading Dose by Maintenance Dose Regimen&nbsp;</strong></p><table><tbody><tr><td>&nbsp;</td><td colspan="3"><p dir="ltr"><strong>Maintenance Dose</strong></p></td></tr><tr><td><p dir="ltr"><strong>Parameters</strong></p></td><td><p dir="ltr"><strong>1.5 mg/kg once every week</strong></p></td><td><p dir="ltr"><strong>3 mg/kg once every two weeks</strong></p></td><td><p dir="ltr"><strong>6 mg/kg once every four weeks</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmax, ss (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>55.1 &plusmn; 15.9</strong></p></td><td><p dir="ltr"><strong>58.3 &plusmn; 16.4</strong></p></td><td><p dir="ltr"><strong>67 &plusmn; 17.7</strong></p></td></tr><tr><td><p dir="ltr"><strong>AUCss,&tau; (&mu;g/mL*day)</strong></p></td><td><p dir="ltr"><strong>376 &plusmn; 109</strong></p></td><td><p dir="ltr"><strong>752 &plusmn; 218</strong></p></td><td><p dir="ltr"><strong>1503 &plusmn; 437</strong></p></td></tr><tr><td><p dir="ltr"><strong>Ctrough, ss (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>51.2&plusmn; 15.2</strong></p></td><td><p dir="ltr"><strong>46.9 &plusmn; 14.8</strong></p></td><td><p dir="ltr"><strong>38.5 &plusmn; 14.2</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmax/ Ctrough ratio (&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>1.08 &plusmn; 0.03</strong></p></td><td><p dir="ltr"><strong>1.26 &plusmn; 0.12</strong></p></td><td><p dir="ltr"><strong>1.85 &plusmn; 0.47</strong></p></td></tr></tbody></table><p dir="ltr"><strong>AUCss,&tau; &nbsp;=&nbsp;area under the concentration time curve at steady-state over the dosing interval (&tau;&nbsp;=&nbsp;1, 2, or 4 weeks); Cmax, ss = maximum plasma concentration at steady state; Ctrough,&nbsp;ss = trough concentration at steady state.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Absorption</strong></p><p dir="ltr"><strong>Following subcutaneous administration, the mean (&plusmn;&nbsp;SD) absorption half-life was 1.6&nbsp;&plusmn; 1 day.</strong></p><p dir="ltr"><strong>The absolute bioavailability following subcutaneous administration of 1&nbsp;mg/kg was between 80.4% and 93.1%. Similar pharmacokinetic profiles were observed following subcutaneous administration in the abdomen, upper arm, and thigh [see section 4.2 Posology and method of administration].</strong></p><p dir="ltr"><strong>Distribution</strong></p><p dir="ltr"><strong>The mean apparent volume of distribution (% coefficient of variation [%CV]) was 10.4&nbsp;L (26.0%).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elimination</strong></p><p dir="ltr"><strong>The mean apparent clearance (%CV) was 0.27&nbsp;L/day (28.4%) and the mean elimination apparent half-life (&plusmn;&nbsp;SD) was 26.9&nbsp;&plusmn; 9.1 days.</strong></p><p dir="ltr"><strong>Specific Populations</strong></p><p dir="ltr"><strong>The pharmacokinetics of emicizumab-kxwh are not influenced by age (1 year to 77 years), race (White 62.7%, Asian 22.9%, and Black 8%), inhibitor status (inhibitor present, 50%), mild hepatic impairment (defined as total bilirubin 1x to 1.5x the upper limit of normal (ULN) and any aspartate transaminase (AST) level), moderate hepatic impairment (defined as total bilirubin 1.5x to 3x the ULN and any AST level), mild renal impairment (defined as creatinine clearance (CrCl) of 60 &ndash; 89 mL/min), and moderate renal impairment (defined as CrCl of 30 &ndash; 59&nbsp;mL/min).</strong></p><p dir="ltr"><strong>In pediatric patients less than 6 months old, the predicted concentrations of emicizumab-kxwh were 19% to 33% lower than the older patients, especially with the 3 mg/kg once every two weeks or 6 mg/kg once every four weeks maintenance dose.</strong></p><p dir="ltr"><strong>In pediatric patients less than 6 months old, the predicted concentrations of emicizumab-kxwh were 19% to 33% lower than the older patients, especially with the 3 mg/kg once every two weeks or 6 mg/kg once every four weeks maintenance dose.</strong></p><p dir="ltr"><strong>Body weight: The apparent clearance and volume of distribution of emicizumab-kxwh increased with increasing body weight (9 kg to 156 kg). Dosing in mg/kg provides similar emicizumab-kxwh exposure across body weight range.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Drug Interaction Studies</strong></p><p dir="ltr"><strong>No drug-drug interaction studies have been conducted with HEMLIBRA.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p dir="ltr"><strong>Studies in animals investigating the carcinogenic effects of emicizumab-kxwh have not been conducted. In vitro and in vivo testing of emicizumab-kxwh for genotoxicity was not conducted.&nbsp;</strong></p><p dir="ltr"><strong>Animal fertility studies have not been conducted; however, emicizumab-kxwh did not cause any toxicological changes in the reproductive organs of male or female cynomolgus monkeys at doses of up to 30 mg/kg/week in subcutaneous general toxicity studies of up to 26-week duration and at doses of up to 100 mg/kg/week in a 4-week intravenous general toxicity study.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>L-Arginine</strong></p><p dir="ltr"><strong>L-Histidine</strong></p><p dir="ltr"><strong>L-aspartic acid</strong></p><p dir="ltr"><strong>Poloxamer 188</strong></p><p dir="ltr"><strong>Water for injection</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>No incompatibilities between Hemlibra and the recommended syringes and needles (see section 6.6) have been observed.</strong></p><p dir="ltr"><strong>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial 
30 months.

Once removed from the refrigerator, unopened vials can be kept at room temperature (below 30⁰C)for up to 7days. 

After storage at room temperature, unopened vials may be returned to the refrigerator. Cumulative storage time at room temperature should not exceed 7 days.

Pierced vial and filled syringe:
Once transferred from the vial to the syringe, the medicinal product should be used immediately, as the medicinal product does not contain any antimicrobial preservatives.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li dir="ltr"><p dir="ltr"><strong>Store HEMLIBRA vials in a refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) in the original carton to protect from light. Do not freeze. Do not shake.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Prior to administration, if needed, unopened vials of HEMLIBRA may be stored out of and then returned to refrigeration. The temperature and total combined time out of refrigeration should not exceed 30&deg;C (86&deg;F) and 7 days (at a temperature below 30&deg;C [86&deg;F]), respectively.&nbsp;</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Once removed from the vial, discard HEMLIBRA if not used immediately.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Discard any unused HEMLIBRA.</strong></p></li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>HEMLIBRA (emicizumab-kxwh) injection is available as a sterile, preservative-free, colorless to slightly yellow solution in single-dose vials in the following dosage strengths:</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Strength</strong></p></td><td><p dir="ltr"><strong>Nominal Volume</strong></p></td><td><p dir="ltr"><strong>Concentration</strong></p></td><td><p dir="ltr"><strong>Package Size (per carton)</strong></p></td><td><p dir="ltr"><strong>Cap Color&nbsp;</strong></p></td><td><p dir="ltr"><strong>NDC</strong></p></td></tr><tr><td><p dir="ltr"><strong>30 mg</strong></p></td><td><p dir="ltr"><strong>1 mL</strong></p></td><td><p dir="ltr"><strong>30 mg/mL</strong></p></td><td><p dir="ltr"><strong>1 vial</strong></p></td><td><p dir="ltr"><strong>Sky Blue</strong></p></td><td><p dir="ltr"><strong>50242-920-01</strong></p></td></tr><tr><td><p dir="ltr"><strong>60 mg</strong></p></td><td><p dir="ltr"><strong>0.4 mL</strong></p></td><td><p dir="ltr"><strong>150 mg/mL</strong></p></td><td><p dir="ltr"><strong>1 vial</strong></p></td><td><p dir="ltr"><strong>Purple</strong></p></td><td><p dir="ltr"><strong>50242-921-01</strong></p></td></tr><tr><td><p dir="ltr"><strong>105 mg</strong></p></td><td><p dir="ltr"><strong>0.7 mL</strong></p></td><td><p dir="ltr"><strong>150 mg/mL</strong></p></td><td><p dir="ltr"><strong>1 vial</strong></p></td><td><p dir="ltr"><strong>Turquoise</strong></p></td><td><p dir="ltr"><strong>50242-922-01</strong></p></td></tr><tr><td><p dir="ltr"><strong>150 mg</strong></p></td><td><p dir="ltr"><strong>1 mL</strong></p></td><td><p dir="ltr"><strong>150 mg/mL</strong></p></td><td><p dir="ltr"><strong>1 vial</strong></p></td><td><p dir="ltr"><strong>Brown</strong></p></td><td><p dir="ltr"><strong>50242-923-01</strong></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>HEMLIBRA is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject, or the patient&rsquo;s caregiver may administer HEMLIBRA, if a healthcare provider determines that it is appropriate. Self-administration is not recommended for children aged&nbsp;less than&nbsp;7 years old.&nbsp;</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Visually inspect HEMLIBRA for particulate matter and discoloration before administration. HEMLIBRA for subcutaneous administration is a colorless to slightly yellow solution. Do not use if particulate matter is visible or product is discolored.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>A syringe, a transfer needle, and an injection needle are needed to withdraw HEMLIBRA solution from the vial and inject it subcutaneously.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Refer to the HEMLIBRA &ldquo;Instructions for Use&rdquo; for handling instructions when combining vials. Do not use different HEMLIBRA vials of different concentrations when combining vials to administer prescribed dose.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Administer doses of HEMLIBRA up to 1 mL with a 1 mL syringe. A 1 mL syringe fulfilling the following criteria may be used: Transparent polypropylene or polycarbonate syringe with Luer-Lok&trade; tip, graduation 0.01&nbsp;mL, sterile, for injection only, single-use, latex-free and non-pyrogenic, commercially available in the US.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Administer doses of HEMLIBRA greater than 1 mL and up to 2 mL with a 2 mL or 3 mL syringe. A 2 mL or 3 mL syringe fulfilling the following criteria may be used: Transparent polypropylene or polycarbonate syringe with Luer-Lok&trade; tip, graduation 0.1&nbsp;mL, sterile, for injection only, single-use, latex-free, and non-pyrogenic, commercially available in the US.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>A transfer needle fulfilling the following criteria may be used: Stainless steel needle with Luer-Lok&trade; connection, sterile, 18&nbsp;gauge, length 1&frac12; inch, semi-blunted tip, single-use, latex-free, and non-pyrogenic, commercially available in the US.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>An injection needle fulfilling the following criteria may be used: Stainless steel with Luer-Lok&trade; connection, sterile, 26 gauge, maximal length &frac12; inch, single-use, latex-free and non-pyrogenic, including needle safety feature, commercially available in the US.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Administer each injection at a different anatomic location (upper outer arms, thighs, or any quadrant of abdomen) than the previous injection. An injection should never be given into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact. Administration of HEMLIBRA in the upper outer arm should only be performed by a caregiver or healthcare provider.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Discard any unused HEMLIBRA remaining in the single-dose vial.</strong></p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124, 
CH-4070 Basel, 
Switzerland.

8.	MARKETING AUTHORISATION NUMBER(S) 

293-24-18
294-24-18
295-24-18
296-24-18


9.	DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

11 December 2018.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04 October 2018.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>